BTK and mantle cell lymphoma: The introduction of Bruton’s tyrosine kinase (BTK) inhibitors has shown promising results in survival outcomes in relapsed/refractory (R/R) MCL and is the primary choice of treatment, especially in patients in the early stages of the disease.